Crizotinib in ALK-Rearranged Inflammatory Myofibroblastic Tumor

By J. Butrynski, D. D’Adamo, J. Hornick, P. Cin, C. Antonescu, S. Jhanwar, Marc Ladanyi, M. Capelletti, S. Rodig, N. Ramaiya and 8 more. New England Journal of Medicine, 2010

803 citations recorded by the source corpus.

SUMMARY Inflammatory myofibroblastic tumor (IMT) is a distinctive mesenchymal neoplasm characterized by a spindle-cell proliferation with an inflammatory infiltrate. Approximately half of IMTs carry rearrangements of the anaplastic lymphoma kinase (ALK) locus on chromosome 2p23, causing aberrant ALK expression. We report a sustained partial response to the ALK inhibitor crizotinib (PF-02341066, Pfizer) in a patient with ALK-translocated IMT, as compared with no observed activity in another patient without the ALK translocation. These results support the dependence of ALK-rearranged tumors on ALK-mediated signaling and suggest a therapeutic strategy for genomically identified patients with the aggressive form of this soft-tissue tumor.

Subfields: Epidemiology, Oncology, Rheumatology

View Paper: https://www.semanticscholar.org/paper/4b97d39d440e086a47197d84842dabb9645bc1e3

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. E. Ewing
2. Z. Du
3. Christine Lovly

In Oncology

1. Z. Du
2. Christine Lovly

In Rheumatology

1. Z. Du
2. Christine Lovly

Citations in the corpus

• Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2012, background): “• mammalian target of rapamycin inhibitors in malignant perivascular epithelioid cell tumours (PEComas), which are often associated with the loss of tuberous sclerosis complex 1 (TSC1)/ TSC2 [32]; • crizotinib in inflammatory myofibroblastic tumour associated with anaplastic lymphoma kinase transloc”
• Mechanisms of receptor tyrosine kinase activation in cancer (2018, positive): “Likewise, oncogenic tyrosine kinase fusions involving ROS1 have been identified in ~ 1% of NSCLCs [112], as well as in IMTs, cholangiocarcinoma, and GBM [94, 113].”